Latent Health Pricing: Specialty Pharmacy Prior Authorization Costs

As an annual enterprise licence, on the evidence available, with the size of the health system's specialty pharmacy operation as the main driver. The inputs a vendor in this position typically uses are the number of specialty medication authorizations and appeals a year, the number of pharmacy sites and 340B covered entities, the EHR footprint to integrate with, and how many of the four product functions are in scope. Some contracts of this type also carry a value component tied to captured prescriptions or recovered 340B savings, which is worth asking about because it changes the incentive on both sides.

The reason to understand the model is that specialty pharmacy authorization is not a cost centre in the way procedural authorization is. A specialty prescription that is approved and filled in the health system's own pharmacy is revenue, and one that leaks to an external pharmacy or is abandoned is lost revenue. Latent's four function framing reflects that: identifying eligible patients and capturing prescriptions are revenue functions, and a licence priced against them will be justified on captured margin rather than saved staff hours.

That is also why a quote for Latent looks nothing like a quote for a general authorization tool, and why comparing the two on price alone misleads. The prior authorization automation use case explains how the specialty pharmacy queue differs from the procedural one.

Included, on the vendor's description, is the clinical AI that reads the chart to answer authorization questions, the authorization and appeal workflow, the patient identification and engagement functions, and 340B compliance support, with a security portal published for review. Latent has stated in press material that it integrates with any EHR, but names no systems on its homepage, so integration is the first thing to price.

• EHR integration. Ask which health system EHRs are in production, by name, and what the interface costs on Latent's side and your EHR vendor's side. Our Epic and Oracle Health pages list the routes a vendor should be able to name, and CoverMyMeds has publicly described a FHIR based electronic prior authorization collaboration with Latent, which is worth asking about for pharmacy benefit requests.
• Scope by function. Whether identify, access, capture and engage are licensed together or separately, and what dropping one does to the price.
• Payer and pharmacy benefit manager coverage. Which plans and PBMs receive submissions electronically and which still go by portal or fax.
• Clinical review staffing. Whether Latent provides pharmacists or technicians to review AI drafted answers, or whether your pharmacy team owns that step.
• Implementation and change management. Fixed price or time and materials, and how many pharmacy staff hours the rollout consumes.

The last point matters more here than in most categories. A model that drafts clinical answers for a specialty medication authorization is producing content submitted under your pharmacists' names, and someone has to review it. That review time is a real cost that no licence line shows.

Within its niche it has few direct competitors on this site, because the other provider side vendors address the procedural and medical authorization queue rather than specialty pharmacy. Waystar quotes an authorization module inside a revenue cycle platform, with third party reports of 100 to 300 USD per provider per month for small practices, and Rhyme quotes a payer network licence against procedural volume. Neither replaces a pharmacy focused product, and a health system may reasonably run one of them alongside Latent.

The comparison that does apply is against your own pharmacy team's manual process and against the electronic prior authorization tools already embedded in your EHR for pharmacy benefit requests, which are often free to the provider because the PBM pays. Availity Essentials, also free, covers medical benefit authorizations for sponsored payers. The question for a Latent quote is what it delivers beyond those free channels, and the answer should be measured in captured prescriptions and appeal wins, not in submissions.

The prior authorization software comparison explains why the shortlists barely overlap.

It is worth it when a health system's specialty pharmacy is large enough that a few points of capture or approval rate are worth more than an enterprise licence. A worked example. A health system's specialty pharmacy handles 2,400 specialty medication authorizations a month. Pharmacy technicians spend an average of 45 minutes on each across chart review, submission and follow up, which is 1,800 hours a month, or about eleven full time equivalents at a loaded cost of roughly 5,200 USD each a month, so around 57,000 USD a month in labour.

If the platform removes half of that time, the labour saving is about 28,500 USD a month. The larger number is capture: if the specialty pharmacy fills 1,500 prescriptions a month at an average margin of 400 USD and a faster, higher approval rate process adds 3 percent to fills, that is 45 more prescriptions and about 18,000 USD a month in margin. Together those two effects set the ceiling an annual licence should be tested against. The assumptions doing the work are the time removed and the capture uplift, and both should be measured in a pilot on one clinic's queue. The prior authorization cost calculator builds the labour side with your own figures, and the denial rate benchmark tells you how much approval rate improvement is realistically available.

For any organisation without its own specialty pharmacy, the capture side of that arithmetic is zero and the case does not close.

• Pilot before licence. One clinic or one drug class, six weeks of baseline and six weeks live, measuring minutes per authorization, days to decision, approval rate and prescriptions captured, with a purchase trigger agreed in advance.
• Function by function pricing so you can license access and appeals first and add capture and engagement when the pilot supports it.
• Value component terms. If any fee is tied to captured prescriptions or 340B savings, the measurement method and audit rights in writing.
• EHR integration named, fixed price, with your EHR vendor's fee identified.
• Human review ownership. A contractual statement of who reviews AI drafted clinical content before submission, and what the vendor warrants about accuracy.
• Model training and retention. Whether your records train any model, how long chart extracts are retained, and the subprocessor list, checked against the HIPAA and AI compliance baseline.
• The business associate agreement and security evidence, requested together before any data moves, since Latent has not published a BAA statement on its main site.
• CMS-0057-F position. The rule's prior authorization API requirements apply to medical benefit requests from impacted payers from January 2027, as set out on our CMS prior authorization rule page; ask how the platform will use those interfaces and what it does to the fee.

Specialty pharmacy authorization is a revenue problem dressed as an administrative one, and the business case depends on capture figures that most health systems have never measured. An independent review builds the baseline, minutes per request, approval rate, days to decision and fills captured by clinic and drug class, so that a Latent proposal has something real to be tested against. It also separates the labour saving, which the pilot can prove, from the capture uplift, which is easier to claim than to measure, and reads the value component and review ownership terms before you sign.

Clunic takes no commissions or referral fees from Latent Health or any other vendor. Our vendor selection service runs the pilot design and quote comparison, and the AI governance and compliance service covers the agreement and evidence review that a clinical AI drafting payer submissions requires. Book a call if your pharmacy team has a Latent proposal on the table.